Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
38 Leser
Artikel bewerten:
(0)

PFC Pharma Joins DATATRAK's CRO Connect Program

CLEVELAND, Nov. 30 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that PFC Pharma Focus AG (PFC) has joined its CRO Connect Program. PFC will now have the ability to contract for DATATRAK's CRO partner training and offer its clients the DATATRAK eClinical(TM) product suite. In addition, PFC will also have access to Partner preferred pricing, business development and joint marketing support. PFC is a premium Contract Research Organization providing international product development services in the pharmaceutical/biotech, life science and health care industries. In addition to its head office in Zurich, Switzerland, further international affiliates include Germany, Israel and India.

"I am very pleased that we can extend our clinical research services with DATATRAK to offer our clients access to a state of the art eClinical solution," said Ran Frenkel, VP Business Development of PFC Pharma Focus Ltd. "Selection of DATATRAK as a partner was a result of rigorous due diligence and a shared vision to provide cost effective technology solutions with the highest levels of credibility and flexibility."

"I am very happy to welcome PFC Pharma Focus to the growing list of DATATRAK CRO Partners," said Laurence Birch, DATATRAK's Chairman of the Board. "As more and more life science companies are turning to CROs to design, manage and conduct their drug programs, DATATRAK continues to expand its list of international CRO Connect Partners. Adopting DATATRAK eClinical(TM) enables both CROs and Sponsors to achieve greater efficiency and visibility in managing their clinical data."

About PFC.

Based in Switzerland, PFC Pharma Focus is a premium contract research organization (CRO), providing product development services in the life science and health care industries. Founded in 1992 by prominent experts in all realms of clinical services, the mission of PFC Pharma Focus is to bring a new look to the drug development experience by addressing the limitations of conventional study practices. This year marks PFC 17 anniversary providing clinical services, and our clients and partners include pharmaceutical, biotechnology, medical device, and academic and government organizations. PFC services encompass clinical development consultancy, clinical operations and project management, medical writing, regulatory affairs, training in pharmaceutical medicine and development of risk management plans.

For more information visit: http://www.pfc-cro.com/. About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology and services company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at http://www.datatrak.net/.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

DATATRAK International, Inc.

CONTACT: Raymond J. Merk, Chief Financial Officer and Chief Operating
Officer, DATATRAK International, Inc., +1-440-443-0082, x181; Ran Frenkel, VP
Business Development, PFC Pharma Focus Ltd., Zurich, Switzerland, +41 44 908
66 66

Web Site: http://www.datatrak.net/

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2009 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.